GSK & ViiV Healthcare Pledge £6M for Community-Led HIV Health Solutions
“`html
GSK and ViiV Healthcare Invest £6 Million in Global Fund to Fight AIDS, TB, and Malaria
Table of Contents
Background: The Global Fund and the Fight Against Infectious Diseases
The Global Fund to Fight AIDS, Tuberculosis and Malaria has been a critical force in global health since 2002, saving an estimated 70 million lives.However, the fight is far from over. Challenges such as climate change, HIV stigma, and the continued devastation caused by tuberculosis require sustained and innovative approaches.
The Global Fund operates on a model of partnership, bringing together governments, the private sector, and communities to address these complex health challenges. Its 8th Replenishment aims to secure funding for the 2027-2029 grant cycle, building on the momentum of recent commitments.
GSK and ViiV Healthcare’s Commitment
Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health GSK said: “We are proud to deepen our partnership with the Global Fund through this catalytic investment, which will help accelerate community-led responses to high burden infectious diseases such as HIV, tuberculosis, and malaria. we believe that sustainable health impact begins with empowering communities and the local organisations that know them best. By supporting programmes that are led by countries, community-owned and community-driven, we’re helping to build stronger, more resilient health systems where they’re needed most.”
This £6 million investment, matched by the Gates Foundation, underscores GSK and ViiV Healthcare’s commitment to global health equity and their belief in the power of community-led initiatives. The focus on empowering local organizations is crucial for ensuring that interventions are tailored to specific needs and contexts.
The Role of the UK and South Africa
The Rt Hon Yvette Cooper MP, Foreign Secretary for the United Kingdom, said: “The Global Fund has saved